impassion130 data demonstrate clinical benefit for immunotherapy in metastatic tnbc
Published 5 years ago • 153 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
4:27
the impassion130 study in metastatic tnbc
-
7:19
impassion130 trial: os updates in metastatic tnbc
-
2:51
impassion130: design and preliminary efficacy
-
4:53
results from the impassion130 trial for triple-negative breast cancer
-
2:30
impassion130: immunotherapy for tnbc
-
5:38
transcode therapeutics begins dosing patients in phase 1 trial for metastatic cancer therapy
-
6:56
impassion130 trial data on pd-l1 tumors in tnbc
-
6:54
impassion130 trial data on pd-l1 tumors in tnbc
-
4:47
tnbc: updated efficacy results from impassion130
-
4:33
i-o in tnbc: impassion130 trial design and results
-
8:42
chemoimmunotherapy in tnbc: the impassion130 trial
-
5:59
impassion130: atezolizumab and nab-paclitaxel in triple-negative breast cancer
-
2:33
applying impassion130 data to tnbc management
-
2:10
testing and targeted therapy in triple negative breast cancer: 2023 west oncology
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
5:45
case 3: atezolizumab/nab-paclitaxel for triple negative breast cancer
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
1:39
dr. rugo on takeaways from the impassion130 trial in tnbc
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer